Dr. Lal PathLabs Limited

NSEI:LALPATHLAB Stok Raporu

Piyasa değeri: ₹253.4b

Dr. Lal PathLabs Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 3/6

Dr. Lal PathLabs kazançlarla iyi bir şekilde karşılanan, mevcut getirisi 0.59% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi, temettüden önceki tarihi 22nd November, 2024 olan 5th November, 2024 dir.

Anahtar bilgiler

0.6%

Temettü verimi

-0.03%

Geri Alım Getirisi

Toplam Hissedar Getirisi0.6%
Gelecekteki Temettü Verimi1.0%
Temettü Büyümesi9.0%
Bir sonraki temettü ödeme tarihi22 Nov 24
Eski temettü tarihi05 Nov 24
Hisse başına temettü₹18.000
Ödeme oranı62%

Son temettü ve geri alım güncellemeleri

Recent updates

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Feb 13
Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dec 29
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

Sep 21
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11
Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: LALPATHLAB 10 yıldan az bir süredir temettü ödüyor ve bu süre zarfında ödemeler dalgalı oldu.

Büyüyen Temettü: LALPATHLAB şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 8 yıldır temettü ödemiştir.


Piyasaya Karşı Temettü Getirisi

Dr. Lal PathLabs Piyasaya Karşı Temettü Getirisi
LALPATHLAB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (LALPATHLAB)0.6%
Pazarın Alt %25'i (IN)0.3%
Pazarın En İyi %25'i (IN)1.1%
Sektör Ortalaması (Healthcare)0.3%
Analist tahmini (LALPATHLAB) (3 yıla kadar)1.0%

Önemli Temettü: LALPATHLAB 'in temettüsü ( 0.59% ), Indian piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 0.25% ) daha yüksektir.

Yüksek Temettü: LALPATHLAB 'in temettüsü ( 0.59% ), Indian piyasasındaki temettü ödeyenlerin en üst %25'ine ( 1.14% ) kıyasla düşüktür.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Makul ödeme oranı ( 62.2% ) ile LALPATHLAB 'un temettü ödemeleri kazançlarla karşılanmaktadır.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Oldukça düşük nakit ödeme oranı ( 30.5% ) ile LALPATHLAB 'un temettü ödemeleri nakit akışları tarafından iyi bir şekilde karşılanmaktadır.


Güçlü temettü ödeyen şirketleri keşfedin